{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2019"],"data_sharing_plan":["IPD Sharing (as of March 2023): No\nDescription: No IPD will be shared"],"condition":["Colorectal Cancer","Colorectal Neoplasms","Advanced metastatic colorectal cancer","Metastatic colorectal cancer"],"disease":["Metastatic Colorectal Cancer","Advanced Metastatic Colorectal Cancer","Colorectal Cancer","Colorectal Neoplasms"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2272605"],"location":["Germany"],"study_start_month":["1"],"keyword":["Ramucirumab","Tas102"],"repository":["ECRIN MDR"],"study_status":["Active, not recruiting"],"additional_accession":[]},"is_claimable":false,"name":"RAMucirumab in Combination Wth TAS102 vs. TAS102 Alone in Chemotherapy Refractory Metastatic Colorectal Cancer Patients","description":"Interventional, prospective, randomized (1:1), controlled, open label, multicenter phase IIb study in patients with advanced metastatic colorectal cancer. The scope of the trial is to evaluate overall survival of either regimen (TAS102 +/- Ramucirumab) and evaluate safety and tolerability.","dates":{"creation":"2019-01-15"},"accession":"2272605","cross_references":{"ClinicalTrials___gov":["NCT03520946"],"EU Clinical Trials Register":["2017-004162-99"]}}